Many drugs are used in the treatment of multiple myeloma but thalidomide, lenalidomide, bortezomib, and dexamethasone and their combination remain the main stay of treatment. The molecular formula of bortezomib is C19H25BN4O4 and its chemical name is (3-methyl-1-(3-phenyl-2-pyrazin-2-ylcarbonylamino-propanoyl) amino-butyl) boronic acid. Mechanisms by which it acts is usually by 26 SProteasome inhibition leading to degradation of anti-apoptotic proteins. Bortezomib is known to cause many side effects. Hence, we report a rare case of bortezomib-induced subconjunctival hemorrhage in our tertiary care hospital.
|Number of pages||2|
|Journal||Asian Journal of Pharmaceutical and Clinical Research|
|Publication status||Published - 01-04-2017|
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science
- Pharmacology (medical)